Open AccessInhibitory Anti-Peroxidasin Antibodies in Pulmonary-Renal Syndromes
Author(s) -
A. Scott McCall,
Gautam Bhave,
Vadim Pedchenko,
Jacob J. Hess,
Meghan E. Free,
Dustin J. Little,
Thomas P. Baker,
William F. Pendergraft,
Ronald J. Falk,
Stephen W. Olson,
Billy G. Hudson
Publication year - 2018
Publication title -
journal of the american society of nephrology
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 4.451
H-Index - 279
eISSN - 1533-3450
pISSN - 1046-6673
DOI - 10.1681/asn.2018050519
Subject(s) - autoantibody , goodpasture syndrome , myeloperoxidase , antibody , podocalyxin , medicine , immunology , rapidly progressive glomerulonephritis , glomerulonephritis , vasculitis , pathogenesis , kidney , pathology , glomerular basement membrane , disease , inflammation , proteinuria , podocyte
Goodpasture syndrome (GP) is a pulmonary-renal syndrome characterized by autoantibodies directed against the NC1 domains of collagen IV in the glomerular and alveolar basement membranes. Exposure of the cryptic epitope is thought to occur via disruption of sulfilimine crosslinks in the NC1 domain that are formed by peroxidasin-dependent production of hypobromous acid. Peroxidasin, a heme peroxidase, has significant structural overlap with myeloperoxidase (MPO), and MPO-ANCA is present both before and at GP diagnosis in some patients. We determined whether autoantibodies directed against peroxidasin are also detected in GP.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom